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A B S T R A C T
Background
Currently, little evidence is available on the length and type of anticoagulation used for extended treatment for prevention of recurrent
venous thromboembolism (VTE) in patients with unprovoked VTE who have completed initial oral anticoagulation therapy.
Objectives
To compare the efﬁcacy and safety of available oral therapeutic options (aspirin, warfarin, direct oral anticoagulants (DOACs)) for
extended thromboprophylaxis in adults with a ﬁrst unprovoked VTE, to prevent VTE recurrence after completion of an acceptable
initial oral anticoagulant treatment period, as deﬁned in individual studies.
Search methods
For this review, the Cochrane Vascular Information Specialist (CIS) searched the Specialised Register (March 2017) as well as the
Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 2). We also searched trials registries (March 2017) and
reference lists of relevant articles.
Selection criteria
We included randomised controlled trials in which patients with a ﬁrst, symptomatic, objectively conﬁrmed, unprovoked VTE, who
had been initially treated with anticoagulants, were randomised to extended prophylaxis (vitamin K antagonists (VKAs), antiplatelet
agents, or DOACs) versus no prophylaxis or placebo. We also included trials that compared one type of extended prophylaxis versus
another type of extended prophylaxis.
Data collection and analysis
Two review authors independently selected studies, assessed quality, and extracted data. We resolved disagreements by discussion.
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Main results
Six studies with a combined total of 3436 participants met the inclusion criteria. Five studies compared extended prophylaxis versus
placebo: three compared warfarin versus placebo, and two compared aspirin versus placebo. One study compared one type of extended
prophylaxis (rivaroxaban) versus another type of extendedprophylaxis (aspirin). For extendedprophylaxis versus placebo,we downgraded
the quality of the evidence for recurrent VTE and all-cause mortality to moderate owing to concerns arising from risks of selection and
performance bias in individual studies. For all other outcomes in this review, we downgraded the quality of the evidence to low owing
to concerns arising from risk of bias for the studies stated above, combined with concerns over imprecision. For extended prophylaxis
versus other extended prophylaxis, we downgraded the quality of the evidence for recurrent VTE and major bleeding to moderate
owing to concerns over imprecision. Risk of bias in the individual study was low.
Meta-analysis showed that extended prophylaxis was no more effective than placebo in preventing VTE-related mortality (odds ratio
(OR) 0.98, 95% conﬁdence interval (CI) 0.14 to 6.98; 1862 participants; 4 studies; P = 0.98; low-quality evidence), recurrent VTE
(OR 0.63, 95% CI 0.38 to 1.03; 2043 participants; 5 studies; P = 0.07; moderate-quality evidence), major bleeding (OR 1.84, 95% CI
0.87 to 3.85; 2043 participants; 5 studies; P = 0.86; low-quality evidence), all-cause mortality (OR 1.00, 95% CI 0.63 to 1.57; 2043
participants; 5 studies; P = 0.99; moderate-quality evidence), clinically relevant non-major bleeding (OR 1.78, 95% CI 0.59 to 5.33;
1672 participants; 4 studies; P = 0.30; low-quality evidence), stroke (OR 1.15, 95% CI 0.39 to 3.46; 1224 participants; 2 studies; P
= 0.80; low-quality evidence), or myocardial infarction (OR 1.00, 95% CI 0.35 to 2.87; 1495 participants; 3 studies; P = 1.00; low-
quality evidence).
One study showed that the novel oral anticoagulant rivaroxaban was associated with fewer recurrent VTEs than aspirin (OR 0.28,
95% CI 0.15 to 0.54; 1389 participants; P = 0.0001; moderate-quality evidence). Data show no clear differences in the incidence
of major bleeding between rivaroxaban and aspirin (OR 3.06, 95% CI 0.37 to 25.51; 1389 participants; P = 0.30; moderate-quality
evidence) nor in the incidence of clinically relevant non-major bleeding (OR 0.84, 95% CI 0.37 to 1.94; 1389 participants; 1 study;
P = 0.69; moderate-quality evidence). Data on VTE-related mortality, all-cause mortality, stroke, and myocardial infarction were not
yet available for participants with unprovoked VTE and will be incorporated in future versions of the review.
Authors’ conclusions
Evidence is currently insufﬁcient to permit deﬁnitive conclusions concerning the effectiveness and safety of extended thromboprophylaxis
in prevention of recurrent VTE after initial oral anticoagulation therapy among participants with unprovoked VTE. Additional good-
quality large-scale randomised controlled trials are required before ﬁrm conclusions can be reached.
P L A I N L A N G U A G E S U M M A R Y
The safety and effectiveness of extending anticoagulant treatment for people who have been treated for blood clots
Background
Venous thromboembolism (VTE) is a condition in which a blood clot forms in the deep veins of the leg or pelvis (deep vein thrombosis
(DVT)), or the clot travels in the blood and blocks a blood vessel in the lungs (pulmonary embolism (PE)). People with a VTE are treated
with an anticoagulant, which prevents formation of further clots. For patients with a VTE that has been caused by a certain risk factor
(prolonged periods of immobility, cancer, pregnancy, oral contraceptives, hormone replacement therapy, trauma, or blood disorder),
treatment can be safely discontinued after three months. However, for patients in whom the VTE has no known cause (unprovoked),
the optimal length of treatment is unknown because evidence is limited. Doctors have to decide upon extended treatment based on
beneﬁt (i.e. prevention of VTE recurrence) and risk (i.e. of bleeding) associated with treatment. This review assessed whether extended
treatment was safe and effective in preventing further clots in patients with an unprovoked VTE.
Study characteristics and key results
We found six studies with a combined total of 3436 patients (until March 2017). Five studies compared treatment with placebo, and
one study compared one type of treatment with another. Three of the ﬁve studies that used a placebo used warfarin, and two used
aspirin. Combining results of the ﬁve studies showed no clear difference in the rate of further clots between patients treated with an
anticoagulant and those treated with a placebo, and no clear difference in the numbers of deaths, bleeding incidents, or adverse effects
such as stroke or heart attack.
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One study showed that oral treatment with the anticoagulant rivaroxaban was associated with fewer clots than aspirin. There was no
evidence of a difference in major and non-major bleeding events between rivaroxaban and aspirin. Data on deaths and deaths related
to clots in the lungs, stroke, and heart attack were not yet available for participants relevant to this review and will be incorporated in
a future version of the review.
Quality of the evidence
The quality of the evidence provided by studies included in this review ranged from low to moderate because a small number of studies
with few events were included.
This review found that trials are too few to show whether extended treatment is safe and effective in preventing further blood clots
after three months’ treatment. Further good-quality and large-scale studies are required.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Extended prophylaxis compared to placebo in patients with unprovoked venous thromboembolism
Patient or population: pat ients with unprovoked venous thromboembolism
Setting: hospital
Intervention: extended prophylaxis
Comparison: placebo
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with extended
prophylaxis
VTE-related mortalitya Study populat ion OR 0.98
(0.14 to 6.98)
1862
(4 RCTs)
⊕⊕©©
LOWb
Two of the four stud-
ies reported no cases of
VTE-related mortality2 per 1000 2 per 1000
(0 to 15)
Recurrent VTEc Study populat ion OR 0.63
(0.38 to 1.03)
2043
(5 RCTs)
⊕⊕⊕©
MODERATEd
170 per 1000 114 per 1000
(72 to 174)
Major bleedinge Study populat ion OR 1.84
(0.87 to 3.85)
2043
(5 RCTs)
⊕⊕©©
LOWf
11 per 1000 20 per 1000
(9 to 40)
All-cause mortalityg Study populat ion OR 1.00
(0.63 to 1.57)
2043
(5 RCTs)
⊕⊕⊕©
MODERATEd
38 per 1000 38 per 1000
(24 to 59)
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Clinically relevant non-
major bleedingh
Study populat ion OR 1.78
(0.59 to 5.33)
1672
(4 RCTs)
⊕⊕©©
LOWf
Two of the four stud-
ies reported no cases of
clinically relevant non-
major bleeding
6 per 1000 11 per 1000
(4 to 31)
Strokei Study populat ion OR 1.15
(0.39 to 3.46)
1224
(2 RCTs)
⊕⊕⊕©
LOWj
10 per 1000 11 per 1000
(4 to 33)
Myocardial infarct ion Study populat ion OR 1.00
(0.35 to 2.87)
1495
(3 RCTs)
⊕⊕⊕©
LOWb
9 per 1000 9 per 1000
(3 to 27)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; OR: odds rat io; RCT: randomised controlled trial; VTE: venous thromboembolism
GRADE Working Group grades of evidence.
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aVTE-related mortality - death due to fatal PE.
bDowngraded as high risk of select ion bias in one study (WARFASA) and high risk of performance bias in another study
(WODIT DVT). The evidence was downgraded further owing to imprecision, ref lected by the small number of outcome events
and wide conf idence intervals around the est imate of ef fect.
cRecurrence rate of symptomatic, object ively conf irmed VTE (DVT or PE) during follow-up.
dDowngraded as high risk of select ion bias in one study (WARFASA) and high risk of performance bias in two studies (WODIT
DVT; WODIT PE).
eMajor bleeding events: A major bleeding episode is def ined as clinically overt bleeding that is associated with at least one
of a fall in haemoglobin levels of 20 g/ L or more; transfusion of at least 2 units of packed red blood cells; involvement of
the intracranial or retroperitoneal space or a body cavity; or death (Internat ional Society on Thrombosis and Haemostasis
def init ion) (Schulman 2005); or as def ined by the invest igators of each trial.
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fDowngraded as high risk of select ion bias in one study (WARFASA) and high risk of performance bias in two studies (WODIT
DVT; WODIT PE). The evidence was downgraded further owing to imprecision, ref lected by the small number of outcome
events and wide conf idence intervals around the est imate of ef fect.
gAll-cause mortality - death due to any cause.
hClinically relevant non-major bleeding as def ined in each individual trial.
iStroke (both ischaemic and haemorrhagic).
jDowngraded as high risk of select ion bias in one study (WARFASA). The evidence was downgraded further owing to
imprecision, ref lected by the small number of outcome events and wide conf idence intervals around the est imate of ef fect.
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B A C K G R O U N D
Description of the condition
Venous thromboembolism (VTE), a disease comprising deep vein
thrombosis (DVT), pulmonary embolism (PE), or both, is a com-
mon (1 to 2 per 1000 person-years) (Oger 2000; Spencer 2006),
preventable, and treatable condition. However, it is a potentially
fatal disease with a short-term mortality rate of approximately
25% (Kyrle 2005; Murin 2002; NSS 2007). Risk of recurrence
during the ﬁrst few weeks after the acute phase of VTE is high
and remains about 10% per year for non-provoked VTE with a
case-fatality rate of 3.6% to 12% (Carrier 2010; Douketis 2007;
Kyrle 2010). The implications of recurrent VTE include not just
mortality but also considerable morbidity with post-thrombotic
syndrome (Leizorovicz 1998). The likelihood of recurrence varies
among patients and is inﬂuenced by several factors including the
presence or absence of trigger risk factors, characteristics of the
index event (proximal DVT or PE compared to distal DVT), and
patients’ clinical features (male sex, post-thrombotic syndrome,
overweight, age). Although risk factors for recurrence have been
identiﬁed, and indeed predictive rules determining duration of
anticoagulation have been developed (Vienna Score,MenDo, and
Her 2 Do from Canada and Italy), these have not been univer-
sally adopted in clinical practice (Eichinger 2010; Rodger 2008;
Tosetto 2012).
VTE can be provoked by triggers, such as a cast, surgery, immobil-
isation, or recent trauma, or unprovoked with no apparent trigger.
Patients with VTE are treated initially with therapeutic parenteral
anticoagulants (usually subcutaneous low molecular weight hep-
arin (LWMH)) and with a vitamin K antagonist (VKA) (i.e. war-
farin). Parenteral therapy is continued until the international nor-
malised ratio (INR) is ≥ 2 for at least 24 hours, after which par-
enteral therapy is stopped. All patients are treated with anticoagu-
lants for at least three months; after this time, it is recommended
to extend treatment for unprovoked VTE if bleeding risk is low
to moderate (Kearon 2012).
Recently, direct oral anticoagulants (DOACs) such as direct factor
Xa inhibitors (apixaban, rivaroxaban, and edoxaban) and direct
thrombin inhibitors (dabigatran) have emerged as a treatment op-
tion in the acute phase of VTE, with similar (or better) efﬁcacy as
VKAs, but with potentially lower bleeding rates and easier admin-
istration (Agnelli 2013; Bauersachs 2010; Hokusai-VTE 2013;
Schulman 2009).
Description of the intervention
Provoked VTE has a low annual risk of recurrence; therefore
oral anticoagulation can be safely discontinued after three months
of therapy (Baglin 2003; Heit 2000; Prandoni 1996; Research
Committee British Thoracic Society 1992; Segal 2007). Treatment
with anticoagulants can signiﬁcantly reduce the recurrence of un-
provoked VTE, but the risk of bleeding is increased during such
treatment. The optimal duration of extended treatment for un-
provoked VTE is unknown because data in the literature are lim-
ited. Physicians have to decide upon extended treatment based on
beneﬁt (i.e. prevention of VTE recurrence) and risk (i.e. of bleed-
ing) due to anticoagulation treatment (Carrier 2010). The risk of
recurrence increases once anticoagulation is stopped, whether a
short or prolonged period of treatment has been recommended
for the patient (Boutitie 2011).
Formany decades, and according to theAmericanCollege ofChest
Physicians guidelines (Kearon 2012), VKA (i.e. warfarin) has been
the drug of choice for long-term treatment of VTE. Warfarin is
not an ideal drug because it has a narrow therapeutic window
and multiple food and drug interactions. Close monitoring and
dose adjustment are required to avoid risk of VTE recurrence or
bleeding, or both (Weitz 2005).
Antiplatelet therapy (i.e. acetylsalicylic acid (aspirin)) may have a
role in long-term prevention of recurrent VTE after initial VKA
therapy for VTE. Two recently published studies reported a re-
duction in VTE recurrence and in major vascular events by a third
(two- to three-fold less than anticoagulants), with low annual risk
of bleeding (0.3%) (Becattini 2012; Brighton 2012).
DOACs such as dabigatran, rivaroxaban, and apixaban have
been studied for extended treatment of VTE after the initial
anticoagulation period, and randomised controlled trials have
been published in recent years (Agnelli 2013; Bauersachs 2010;
Schulman 2013). When compared to placebo or warfarin, all
DOACs demonstrated efﬁcacy in reducing VTE recurrence, some
with lower bleeding rates compared to warfarin (Agnelli 2013;
Bauersachs 2010; Schulman 2013). When compared to placebo,
data show increased bleeding rates with dabigatran and rivaroxa-
ban but no increase in the rate of major bleeding with apixaban
(Agnelli 2013; Bauersachs 2010; Schulman 2013).
Investigators have identiﬁed risk factors for recurrence of VTE
and have developed predictive scores to determine the duration
of anticoagulation (Eichinger 2010; Rodger 2008; Tosetto 2012).
Overall, none of these models has been incorporated into clinical
use because management studies and external prospective valida-
tion are still needed.
Why it is important to do this review
Prolonged treatment with anticoagulation prevents VTE recur-
rence. However, current standard treatment with a VKA is associ-
ated with bleeding complications. Thus, questions regarding du-
ration of therapy for secondary prevention of VTE recurrence, and
which is the best anticoagulant to achieve this goal, remain open.
DOACs or antiplatelet agents may offer a simple and relatively
safe alternative to VKAs for preventing secondary VTE in patients
with unprovoked VTE. No Cochrane review has compared avail-
able oral therapeutic options (aspirin, warfarin, and DOACs). To
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date, best evidence to guide decision making for the optimal dura-
tion of extended prophylaxis or the type of oral anticoagulant for
preventing secondary unprovoked VTE is lacking. To determine
the best oral anticoagulant currently available for secondary pre-
vention of VTE, we will perform a systematic review and meta-
analysis of all randomised controlled trials currently available in
the literature. We intend to reach this decision by ascertaining the
efﬁcacy of oral anticoagulants in preventing VTE recurrence and
their safety as regards bleeding complications.
O B J E C T I V E S
To compare the efﬁcacy and safety of available oral therapeutic
options (aspirin, warfarin, direct oral anticoagulants (DOACs))
for extended thromboprophylaxis in adultswith a ﬁrst unprovoked
VTE, to prevent VTE recurrence after completion of an acceptable
initial oral anticoagulant treatment period, as deﬁned in individual
studies.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials, irrespective of language, date of pub-
lication, and publication status. We excluded studies administer-
ing drugs that have been removed from the market (e.g. ximelaga-
tran). We excluded studies on treatment of individuals with acute-
phase VTE as well as people with provoked VTE.
Types of participants
Adult participants (> 18 years) with their ﬁrst symptomatic, ob-
jectively conﬁrmed, unprovoked VTE after completion of an ac-
ceptable initial oral anticoagulant treatment period, as deﬁned by
individual studies.
Types of interventions
Oral therapeutic options for extended thromboprophylaxis in-
clude VKAs (including warfarin), antiplatelet agents (including
aspirin), and DOACs (including dabigatran, rivaroxaban, edoxa-
ban, and apixaban).
We considered two types of comparisons.
• VTE extended prophylaxis (antiplatelets, DOACs, or
VKAs) versus no prophylaxis or placebo.
• VTE extended prophylaxis (antiplatelets, DOACs, or
VKAs) versus any other VTE extended prophylaxis (antiplatelets,
DOACs, or VKAs).
Extended prophylaxis is deﬁned as treatment for participants with
VTE who have completed at least three months and up to four
years of anticoagulation therapy after initial treatment.
Types of outcome measures
Primary outcomes
• VTE-related mortality
• Recurrence rate of symptomatic, objectively conﬁrmed
VTE (DVT or PE) during follow-up
• Major bleeding: A major bleeding episode is deﬁned as
clinically overt bleeding that is associated with at least one of a fall
in haemoglobin levels of 20 g/L or more; transfusion of at least 2
units of packed red blood cells; involvement of the intracranial
or retroperitoneal space or a body cavity; or death (International
Society on Thrombosis and Haemostasis (ISTH) deﬁnition)
(Schulman 2005); or as deﬁned by the investigators in each trial
Secondary outcomes
• All-cause mortality
• Clinically relevant non-major bleeding: bleeding that is
clinically overt but does not meet the deﬁnition of serious
bleeding provided by the ISTH (Schulman 2005)
• Stroke (both ischaemic and haemorrhagic) or transient
ischaemic attack (TIA)
• Serious adverse events, including acute myocardial
infarction; acute coronary syndrome; or any life-threatening or
grade 3 to 4 non-haematological event (such as hepatotoxicity or
renal toxicity)
Search methods for identification of studies
Electronic searches
The Cochrane Vascular Information Specialist (CIS) searched the
following databases for relevant trials.
• Cochrane Vascular Specialised Register (March 2017).
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2017, Issue 2) via the Cochrane Register of Studies
Online.
See Appendix 1 for details of the search strategy used to search
CENTRAL.
The CIS maintains the Cochrane Vascular Specialised Register,
which is constructed through weekly electronic searches of MED-
LINE Ovid, Embase Ovid, the Cumulative Index to Nursing and
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Allied Health Literature (CINAHL), and the Allied and Comple-
mentary Medicine Database (AMED), and through handsearch-
ing of relevant journals. The full list of databases, journals, and con-
ference proceedings searched and the search strategies used are pre-
sented in the Specialised Register section of theCochrane Vascular
Module in the Cochrane Library (www.cochranelibrary.com).
The CIS also searched the following trial registries for details of
ongoing and unpublished studies (March 2017).
• CinicalTrials.gov (www.clinicaltrials.gov).
• World Health Organization International Clinical Trials
Registry Platform (www.who.int/trialsearch).
• ISRCTN Register (www.isrctn.com/).
See Appendix 2 for details of these searches.
Searching other resources
We checked the citations of included trials and major reviews for
additional studies.
When necessary, we contacted the ﬁrst or corresponding author
of included studies to obtain additional trial information.
Data collection and analysis
Selection of studies
Two review authors (LR, and AR or SEY) inspected the title and,
when available, the abstract of each reference identiﬁed in the
search and applied the inclusion criteria. When relevant articles
were identiﬁed, we obtained the full article and two review authors
independently inspected the article and applied the inclusion cri-
teria. In the case of disagreement between the two review authors,
the third review author independently applied the inclusion crite-
ria. We documented the justiﬁcation for excluding studies.
We included trials regardless of publication status and date and
language of publication. We excluded trials regarding anticoagu-
lants that are currently, or were previously, omitted from the mar-
ket (e.g. ximelagatran). We also excluded trials that included par-
ticipants with other indications or contraindications for treatment
with anticoagulants or antiaggregants; or participants treated with
other antiplatelet agents or non-steroidal anti-inﬂammatory drugs
(NSAIDs).
Data extraction and management
Two review authors (LR, and AR or SEY) independently extracted
the following data using data extraction forms.
• Study design.
• Length of follow-up.
• Dates of study.
• Location and setting of study.
• Characteristics of participants: number, age, sex, ethnic
group.
• Previous DVT or PE.
• Type of VTE at initial diagnosis (DVT, PE, etc.).
• Creatinine clearance.
• Methodological quality (risk of bias).
• Characteristics of interventions (name of drug, dose,
duration of treatment).
• Description of primary and secondary outcomes (as deﬁned
above).
We resolved disagreements by discussion. If disagreement per-
sisted, the third review author extracted the data independently.
Wediscussed data extraction, documenteddisagreements and their
resolution, and, when necessary, contacted study authors to re-
quest clariﬁcation. If this was unsuccessful, we reported disagree-
ments.
Assessment of risk of bias in included studies
Two review authors (LR, AR or SEY) independently assessed trials
for methodological quality. We described and assessed allocation
concealment, sequence generation, blinding, incomplete outcome
data, and selective outcome reporting individually, according to
Cochrane’s tool for assessing bias, as described in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We resolved disagreements by discussion. If disagreement per-
sisted, the third review author assessed trials for methodological
quality.
Measures of treatment effect
We estimated odds ratios (ORs) with 95% conﬁdence intervals
(CIs) for dichotomous data using the Mantel-Haenszel method.
Unit of analysis issues
The unit of analysis was the individual participant.
We did not include cross-over trials and cluster-randomised trials.
Dealing with missing data
When data were missing, we attempted to contact study authors
to request the missing information.
We planned to impute missing dichotomous data for participants
who were lost to follow-up after randomisation, assuming a poor
outcome (worse-case scenario) for missing individuals. However,
as few participants were lost to follow-up in the studies included
in this review, it was not possible to do this.
We planned to perform a sensitivity analysis of the primary out-
come while excluding trials in which more than 20% of partici-
pants were lost to follow-up.
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Assessment of heterogeneity
We assessed heterogeneity (the degree of difference between results
of different trials) using the Chi2 test of heterogeneity and the I2
statistic for inconsistency, as described in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). We deﬁned
statistically signiﬁcant heterogeneity as P value < 0.10, or an I2
statistic greater than 50%. An I2 < 25% was considered to show
low-level heterogeneity, and 25% to 50% moderate-level hetero-
geneity.
Assessment of reporting biases
We planned to assess publication bias by preparing funnel plots
if a sufﬁcient number of studies (10 or more) were available in
the meta-analyses. Funnel plot asymmetry can be used for many
reasons, and we planned to consult the Cochrane Handbook for
Systematic Reviews of Interventions to aid interpretation of these
results (Sterne 2011).
Data synthesis
We entered the data into RevMan 5 (RevMan 2014) and un-
dertook analysis according to recommended guidelines (Higgins
2011). We pooled ORs with 95% CIs for dichotomous data. We
reported exclusions after randomisation and used a ﬁxed-effect
model (Mantel-Haenszel method) unless signiﬁcant heterogeneity
(P < 0.10) was detected, in which case we used a random-effects
model (DerSimonian 1986). If it was not possible to pool data,
we described results in the text.
Subgroup analysis and investigation of heterogeneity
We explored potential sources of heterogeneity by stratifying par-
ticipants using the subgroups given below.
• Types of comparison intervention (type of drug).
• Age (≤ 65 years, > 65 years).
• Sex.
• Renal function.
We also planned to perform a subgroup analysis according to the
duration of initial therapy in the acute phase of VTE.
We formally assessed differences between subgroups by using the
Chi2 test.
Sensitivity analysis
We planned to perform sensitivity analyses to examine effects of
different trials and their methods, as described in Chapter 9 (Sec-
tion 9.7) of the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011); therefore, we conducted a sensitivity
analysis while excluding studies at high risk of bias due to inade-
quate allocation concealment.
We also planned to perform a sensitivity analysis of the primary
outcome while excluding trials in which more than 20% of par-
ticipants were lost to follow-up.
When we identiﬁed heterogeneity, we performed a post hoc sen-
sitivity analysis to investigate effects of the type of baseline VTE.
’Summary of findings’
We presented the main ﬁndings of the review in a ’Summary of
ﬁndings’ table, reporting the quality of evidence (according to
Atkins 2004), the magnitude of effect of interventions examined,
and the sum of available data on VTE-related mortality; recur-
rence rate of symptomatic, objectively conﬁrmed VTE (DVT or
PE) during follow-up; and major bleeding events. We calculated
assumed control intervention risks from the mean numbers of
events in the control groups of selected studies for each outcome.
We used GRADEpro software to assist in preparation of the ’Sum-
mary of ﬁndings’ table (GRADEproGDT 2015).
R E S U L T S
Description of studies
Results of the search
See Figure 1.
10Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked
venous thromboembolism (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Study flow diagram.
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Included studies
We included in the review six completed studies with a total
of 3436 participants (ASPIRE TRIAL; EINSTEIN CHOICE;
PADIS-PE STUDY; WARFASA; WODIT DVT; WODIT PE).
For detailed descriptions, see Characteristics of included studies.
ASPIRE TRIAL was a randomised, double-blind study in which
822 participants with a ﬁrst-ever unprovoked VTE who had com-
pleted at least three months of anticoagulant therapy were ran-
domised to receive aspirin at a dose of 100 mg or placebo for a
period of two years. Outcomes included recurrent VTE, major
cardiovascular events (stroke, myocardial infarction (MI), cardio-
vascular death), death from any cause, and bleeding (major and
clinically relevant non-major).
EINSTEIN CHOICE was a multi-centre, randomised, double-
blind, active controlled, event-driven study that compared two
once-daily doses of rivaroxaban (20 and 10mg) versus aspirin (100
mg) once daily for prevention of recurrent VTE in 3365 partici-
pants who had completed 6 to 12 months of anticoagulant ther-
apy for their index acute VTE event. For analysis in this review,
we included only participants given a diagnosis of an unprovoked
VTE as the index event (1389 participants). Primary outcomes
included recurrent VTE and major bleeding. Secondary outcomes
included MI, stroke, clinically relevant non-major bleeding, and
all-cause mortality. Data on secondary outcomes and VTE mor-
tality for participants with unprovoked VTE were not available
in the main publication of the study, nor in the supplementary
material. We contacted study authors to ask for these data, but
they could not provide this information before completion of this
review. Once the data are acquired, we will add them to future
updates of this review.
PADIS-PE STUDY was a randomised, double-blind study in
which 374 participants with a ﬁrst-ever unprovokedVTEwhohad
completed at least six uninterrupted months of VKA therapy were
randomised to receive warfarin or placebo for 18 months. Out-
comes included recurrent VTE, VTE-related mortality, bleeding
(major and clinically relevant non-major), and death from causes
other than VTE.
WARFASA was a randomised, double-blind study in which 403
participants with a ﬁrst-ever unprovokedVTEwhohad completed
6 to 18 months of anticoagulant therapy were randomised to re-
ceive aspirin 100 mg daily or placebo for a duration of two years.
Outcomes included recurrent VTE, VTE-relatedmortality, bleed-
ing (major and clinically relevant non-major), stroke, and MI.
WODIT PE was an open-label RCT in which 181 participants
with a ﬁrst episode of PE who had been treated for three months
were randomly assigned to extended prophylaxis or to no fur-
ther anticoagulation. Participants were divided into two groups:
those who had an idiopathic PE, and those who had a PE associ-
ated with a transient risk factor, including cancer, known throm-
bophilia, recent trauma, surgery or childbirth, prolonged immo-
bilisation > 7 days, oral contraceptive use, or pregnancy. In total,
the study included 326 participants, but for the purpose of this
review, we included only 181 participants with idiopathic PE who
were randomised to continue warfarin therapy for nine months
or to discontinue anticoagulation. Outcomes included recurrence
of symptomatic, objectively conﬁrmed VTE, death, and major
bleeding.
WODIT DVT was similar to WODIT PE, except that the study
included 267 participants with an unprovoked DVT.
Excluded studies
See Characteristics of excluded studies.
In total, we excluded 15 studies from this review. We excluded
seven studies because they included participants with known risk
factors for VTE, including recent surgery or trauma, immobilisa-
tion, oestrogen therapy, active cancer or puerperium, and throm-
bophilia or other hypercoagulable states associated with increased
risk of VTE (EINSTEIN-Extension; Eischer 2009; Gibson 2017;
Kearon 1999; PREVENT; RE-MEDY; RE-SONATE). We ex-
cluded three studies because they looked at initial anticoagu-
lant treatment of acute VTE rather than extended prophylaxis
(EINSTEIN STUDY; Nakamura 2015; RE-COVER). We ex-
cluded two studies that included participants with a previous VTE
(AMPLIFY EXT; Bleker 2016); one study that tested sulodex-
ide, an LMWH (SURVET); and another study that tested idra-
parinux, which is an injectable rather than an oral anticoagulant
(VAN GOGH). Last, we excluded one study because the primary
outcome was the size of thrombotic masses, which is not relevant
to our review (Vitovec 2009).
Ongoing studies
See Characteristics of ongoing studies.
We included one study as an ongoing study (NCT00740493).
The PADIS-TVP study is a randomised, double-blind study in
which 104 participants with a ﬁrst-ever unprovoked, proximal
DVT who had completed at least six uninterrupted months of
VKA therapy were randomised to receive warfarin or placebo for
18 months. Outcomes included symptomatic recurrent VTE and
bleeding and death from causes other than VTE.
Risk of bias in included studies
For details on methodological quality of included studies, see
Figure 2 and Figure 3.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Four of the six included studies reported that random sequences
were generated by central computerised Internet-based systems;
therefore, we judged risk of selection bias in these studies as low
(ASPIRE TRIAL; EINSTEIN CHOICE; PADIS-PE STUDY;
WARFASA). The remaining two studies did not provide infor-
mation on how the randomisation sequence was generated; we
therefore judged the risk of selection bias to be unclear (WODIT
DVT; WODIT PE).
For concealment of treatment allocation, ﬁve studies reported that
this was done centrally; we therefore judged them to be at low risk
(ASPIRE TRIAL; EINSTEIN CHOICE; PADIS-PE STUDY;
WODIT DVT; WODIT PE). One study reported that partici-
pants were randomised according to the consecutive box number
assigned to the study centre (WARFASA). As participants or inves-
tigators enrolling participants could possibly foresee assignments,
we judged the risk of selection bias in this study to be high.
Blinding
Two studies were open trials comparing warfarin with a placebo
(WODIT DVT; WODIT PE). Blinding could have been per-
formed by using an identical-looking placebo and sham INRs.
Therefore we judged the risk of performance bias in these two
studies as high. The remaining four studies blinded participants
and personnel to treatment; therefore we deemed the risk of per-
formance bias to be low (ASPIRE TRIAL; EINSTEINCHOICE;
PADIS-PE STUDY; WARFASA).
All six studies blinded outcome assessors to treatment; therefore
we judged these studies to be at low risk of detection bias (ASPIRE
TRIAL; EINSTEINCHOICE; PADIS-PE STUDY;WARFASA;
WODIT DVT; WODIT PE).
Incomplete outcome data
All six included studies accounted for missing data; we there-
fore judged them to be at low risk of attrition bias (ASPIRE
TRIAL; EINSTEINCHOICE; PADIS-PE STUDY;WARFASA;
WODIT DVT; WODIT PE).
Selective reporting
All six of the included studies reported prespeciﬁed primary and
secondary outcomes; therefore we judged them to be at low risk of
reporting bias (ASPIRE TRIAL; EINSTEIN CHOICE; PADIS-
PE STUDY; WARFASA; WODIT DVT; WODIT PE).
Other potential sources of bias
All six included studies appeared to be free from other sources
of bias (ASPIRE TRIAL; EINSTEIN CHOICE; PADIS-PE
STUDY; WARFASA; WODIT DVT; WODIT PE).
Effects of interventions
See: Summary of findings for the main comparison
Extended prophylaxis compared to placebo in patients with
unprovoked venous thromboembolism; Summary of findings
2 VTE extended prophylaxis compared to another VTE
extended prophylaxis in patients with unprovoked venous
thromboembolism
We identiﬁed ﬁve studies investigating prophylaxis versus placebo
and one study comparing one type of extended prophylaxis versus
another type of extended prophylaxis.
VTE extended prophylaxis versus placebo or no
prophylaxis
VTE-related mortality
Four studies measured the incidence of VTE-related mortality be-
tween extended VTE prophylaxis and placebo (ASPIRE TRIAL;
PADIS-PE STUDY; WARFASA; WODIT DVT). Overall, data
showed no clear differences in VTE-related mortality between ex-
tended VTE prophylaxis and placebo (OR 0.98, 95% CI 0.14 to
6.98; 1862 participants; I2 = 0%). However, in the two studies
comparing warfarin to placebo, no VTE-related deaths occurred
(PADIS-PE STUDY; WODIT DVT). Subgroup analysis accord-
ing to type of comparison intervention therefore was not applica-
ble (Analysis 1.1).
Recurrent VTE
Meta-analysis of ﬁve studies with a total of 2043 participants
showed no clear difference in recurrence between extended VTE
prophylaxis and placebo (OR 0.63, 95% CI 0.38 to 1.03; 2043
participants; I2 = 66%). However, the level of statistical hetero-
geneity was high when these studies were combined. Subgroup
analysis performed for warfarin showed no clear differences be-
tween participants treated with warfarin and those given a placebo
or no further prophylaxis (OR0.52, 95%CI0.15 to 1.80; 819 par-
ticipants; 3 studies; I2 = 83%; Analysis 1.2). Of the three warfarin
studies, one study included participants withDVT only (WODIT
DVT), one included participants with PE only (WODIT PE),
and one included participants predominantly given a diagnosis
of PE with a small proportion (8.4%) given a diagnosis of DVT
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(PADIS-PE STUDY). When we excluded this study from the
analysis, heterogeneity disappeared (I2 = 0%). Subgroup analysis
comparing aspirin versus placebo showed that the rate of recurrent
VTEwas lower in patients treatedwith placebo (OR0.68, 95%CI
0.50 to 0.92; 1224 participants; 2 studies; I2 = 0%; Analysis 1.2).
Tests for subgroup differences showed no differences between the
two types of comparison interventions (P = 0.68) (Analysis 1.2).
Major bleeding
Meta-analysis of ﬁve studies showed no clear differences in the
incidence of major bleeding between extended VTE prophylaxis
and placebo (OR 1.84, 95% CI 0.87 to 3.85; 2043 participants;
5 studies; I2 = 0%). Subgroup analysis performed for two types of
drugs found no association for warfarin (OR 2.81, 95% CI 0.89
to 8.92; 819 participants; 3 studies; I2 = 0%) nor for aspirin (OR
1.28, 95%CI 0.47 to 3.47; 1224 participants; 2 studies; I2 = 0%).
Tests for subgroup differences showed no differences between the
two types of comparison interventions (P = 0.31) (Analysis 1.3).
All-cause mortality
Meta-analysis of ﬁve studies showed no clear differences in the in-
cidence of all-cause mortality between extended VTE prophylaxis
and placebo (OR 1.00, 95% CI 0.63 to 1.57; 2043 participants;
I2 = 0%). Analysis performed for two types of comparison inter-
ventions (warfarin and aspirin) showed no association for warfarin
(OR 1.07, 95% CI 0.53 to 2.17; 819 participants; 3 studies; I2 =
0%) nor for aspirin (OR 0.95, 95% CI 0.52 to 1.72; 1224 partic-
ipants; 2 studies; I2 = 0%). Tests for subgroup differences showed
no differences between the two types of comparison interventions
(P = 0.79) (Analysis 1.4).
Clinically relevant non-major bleeding
Four studies measured the incidence of clinically relevant non-
major bleeding between extended VTE prophylaxis and placebo
(OR 1.78, 95% CI 0.59 to 5.33; 1672 participants; I2 = 0%).
However, in the two studies comparingwarfarin versus placebo, no
clinically relevant non-major bleeding events occurred (WODIT
DVT; WODIT PE). Subgroup analysis performed for aspirin
found no association (OR 1.78, 95% CI 0.59 to 5.33; 1224 par-
ticipants; 2 studies; I2 = 0%) (Analysis 1.5).
Stroke
Meta-analysis of two studies showed no evidence of a difference
in the incidence of stroke between extended VTE prophylaxis
with aspirin and placebo (OR 1.15, 95% CI 0.39 to 3.46; 1224
participants; I2 = 0%) (Analysis 1.6).
Serious adverse events
Myocardial infarction
Meta-analysis of three studies showed no evidence of a difference
in the incidence of myocardial infarction between extended VTE
prophylaxis and placebo (OR 1.00, 95% CI 0.35 to 2.87; 1495
participants; 3 studies; I2 = 0%). Analysis performed for two types
of comparison interventions (warfarin and aspirin) found no asso-
ciation for warfarin (OR 1.02, 95% CI 0.20 to 5.16; 271 partic-
ipants; 1 study) nor for aspirin (OR 0.98, 95% CI 0.24 to 3.94;
1224 participants; 2 studies; I2 = 0%). Tests for subgroup differ-
ences showed no differences between the two types of comparison
interventions (P = 0.97) (Analysis 1.7).
None of the included studiesmeasured other serious adverse events
such as acute coronary syndrome or any life-threatening or grade
3 to 4 non-haematological events (such as hepatotoxicity or renal
toxicity).
VTE extended prophylaxis versus another VTE
extended prophylaxis
VTE-related mortality
The EINSTEIN CHOICE study measured fatal PE but reported
it for the total number of study participants rather than separately
for provoked and unprovoked VTE groups. We contacted study
authors to ask for these data, but they could not provide this
information before completion of this review. Once the data are
acquired, we will add them to future updates of this review.
Recurrent VTE
One study measured the incidence of recurrent VTE between two
types of extended prophylaxis and showed that rivaroxaban was
associatedwith a lowerVTE recurrence rate than aspirin (OR0.28,
95%CI 0.15 to 0.54; 1389 participants) (EINSTEINCHOICE).
Major bleeding
One study measured the incidence of major bleeding between two
types of extended prophylaxis and showed no clear differences in
the number of major bleeding events between rivaroxaban and
aspirin (OR 3.06, 95% CI 0.37 to 25.51; 1389 participants) (
EINSTEIN CHOICE).
All-cause mortality
Although all-cause mortality was a secondary outcome of the
EINSTEIN CHOICE study, researchers did not present data in
the study publication nor in the supplementary material for study
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participants with unprovoked VTE. We contacted study authors
to ask for the data, and they stated that they would provide this
information. However, the data were not available before publi-
cation of this review. Once the data have been received, we will
include them in future updates of this review.
Clinically relevant non-major bleeding
One studymeasured the incidence of clinically relevant non-major
bleeding and showed no clear differences in the number of non-
major bleeding events between rivaroxaban and aspirin (OR 0.84,
95%CI 0.37 to 1.94; 1389 participants) (EINSTEINCHOICE).
Stroke
Although stroke was a secondary outcome of the EINSTEIN
CHOICE study, study authors did not present data in the study
publication nor in the supplementary material for study partici-
pants with unprovoked VTE. We contacted study authors to ask
for the data, and they stated that they would provide this infor-
mation. However, the data were not available before publication
of this review. Once the data have been received, we will included
them in future updates of this review.
Serious adverse events
Although serious adverse events such as MI were a secondary out-
come of the EINSTEIN CHOICE study, study authors did not
present data in the study publication nor in the supplementary
material for study participants with unprovoked VTE. We con-
tacted study authors to ask for the data, and they stated that they
would provide this information. However, the data were not avail-
able before publication of this review. Once the data have been
received, we will include them in future updates of this review.
Subgroup analyses
We planned subgroup analyses by age (≤ 65 years, > 65 years), sex,
renal function, and duration of initial therapy in the acute phase
of VTE. However, we could not perform these subgroup analyses
because participant-level data were insufﬁcient.
Sensitivity analyses
We performed sensitivity analyses according to the risk of bias
item allocation concealment. One study did not adequately con-
ceal treatment allocation; we therefore judged this study to be at
high risk of selection bias (WARFASA). Excluding this study had
no effect on the results for any outcomes. Extended prophylaxis
was no more effective than placebo for prevention of VTE-related
mortality (OR 1.00, 95% CI 0.06 to 16.04), recurrent VTE (OR
0.62, 95% CI 0.31 to 1.24), major bleeding (OR 1.52, 95% CI
0.77 to 3.01), all-causemortality (OR0.97, 95%CI 0.59 to 1.59),
clinically relevant non-major bleeding (OR 3.03, 95% CI 0.61
to 15.10), stroke (OR 0.80, 95% CI 0.21 to 2.99), nor serious
adverse events (myocardial infarction) (OR 1.01, 95% CI 0.29 to
3.53).
We planned to perform a sensitivity analysis of the primary out-
come while excluding trials in which more than 20% of partici-
pants were lost to follow-up. However, none of the included stud-
ies had a 20% loss to follow-up, so it was not possible to perform
this analysis.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
VTE extended prophylaxis compared to another VTE extended prophylaxis in patients with unprovoked venous thromboembolism
Patient or population: pat ients with unprovoked venous thromboembolism
Setting: hospital
Intervention: extended prophylaxis (rivaroxaban)
Comparison: extended prophylaxis (aspirin)
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with aspirin Risk with rivaroxaban
VTE-related mortalitya See comments. See comments. See comments. See comments. Data on VTE-related
mortality are yet avail-
able for part icipants
with unprovoked VTE
Recurrent VTEb Study populat ion OR 0.28
(0.15 to 0.54)
1389
(1 RCT)
⊕⊕⊕©
MODERATEc
56 per 1000 16 per 1000
(9 to 31)
Major bleedingd Study populat ion OR 3.06
(0.37 to 25.51)
1389
(1 RCT)
⊕⊕⊕©
MODERATEc
2 per 1000 7 per 1000
(1 to 52)
All-cause mortalitye See comments. See comments. See comments. See comments. Data on all-cause mor-
tality are not yet avail-
able for part icipants
with unprovoked VTE
Clinically relevant non-
major bleedingf
19 per 1000 16 per 1000
(7 to 37)
OR 0.84
(0.37 to 1.94)
1389
(1 RCT)
⊕⊕⊕©
MODERATEc
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Strokeg See comments. See comments. See comments. See comments. Data on stroke are not
yet available for part ic-
ipants with unprovoked
VTE
Myocardial infarct ion See comments. See comments. See comments. See comments. Data on myocardial in-
farct ion are not yet
available for part ici-
pants with unprovoked
VTE
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; OR: odds rat io; RCT: randomised controlled trial; VTE: venous thromboembolism
GRADE Working Group grades of evidence.
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aVTE-related mortality - death due to fatal PE.
bRecurrence rate of symptomatic, object ively conf irmed VTE (DVT or PE) during follow-up.
cThe evidence was downgraded owing to imprecision, ref lected by the small number of outcome events and wide conf idence
intervals around the est imate of ef fect.
dMajor bleeding events: A major bleeding episode is def ined as clinically overt bleeding that is associated with at least one
of a fall in haemoglobin levels of 20 g/ L or more; transfusion of at least 2 units of packed red blood cells; involvement of
the intracranial or retroperitoneal space or a body cavity; or death (Internat ional Society on Thrombosis and Haemostasis
def init ion) (Schulman 2005); or as def ined by the invest igators of each trial.
eAll-cause mortality - death due to any cause.
fClinically relevant non-major bleeding as def ined in each individual trial.
gStroke (both ischaemic and haemorrhagic).
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D I S C U S S I O N
Summary of main results
Venous thromboembolism (VTE) extended
prophylaxis versus placebo or no prophylaxis
Our review includedﬁve studieswithmore than2000participants,
and meta-analysis found no evidence that extended prophylaxis
is favourable over placebo in terms of preventing recurrent VTE,
death, bleeding, and serious adverse events such as stroke and my-
ocardial infarction. Subgroup analysis revealed that placebo may
be favourable over aspirin for prevention of recurrent VTE.
VTE extended prophylaxis versus another VTE
extended prophylaxis
One included study with more than 1300 participants with un-
provoked VTE compared one type of extended VTE prophylaxis
versus another. Results showed that rivaroxaban was associated
with a lower VTE recurrence rate than aspirin and showed no clear
differences in major bleeding or non-major bleeding episodes be-
tween rivaroxaban and aspirin.
Overall completeness and applicability of
evidence
At present, limited evidence is available to show whether oral
therapeutic options such as aspirin, warfarin, and direct oral an-
ticoagulants (DOACs) are effective and safe extended thrombo-
prophylaxis for patients with a ﬁrst unprovoked VTE who have
completed at least three months of initial oral anticoagulation.
Six studies met the inclusion criteria for this review (ASPIRE
TRIAL; EINSTEINCHOICE; PADIS-PE STUDY;WARFASA;
WODITDVT;WODIT PE). Five studies compared prophylaxis
versus placebo, and one study compared one type of prophylaxis
versus another. Three studies compared warfarin, and two aspirin,
versus placebo. All studies used similar concentrations of each
drug and the standard International Society on Thrombosis and
Haemostasis (ISTH) deﬁnition of major bleeding. As all trials had
strict inclusion criteria, resulting in an overall participant popu-
lation with almost identical conditions, statistical heterogeneity
was low for all outcomes except recurrent VTE. However, the
time frame for measuring outcomes ranged from 9 months to 37
months among studies. Some studies measured outcomes at the
end of the treatment period, and others measured outcomes at the
end of follow-up. This could result in a situation where, if treat-
ment is efﬁcient, a difference is shown during and at the end of the
treatment period but disappears during follow-up. As such, the
two groups would have similar overall event rates. Furthermore,
the number of participants in each study was relatively small, and
pooled analysis was based on a total of 3436 participants.
Data on VTE mortality and secondary outcomes for the
EINSTEIN CHOICE study were not available in the main pub-
lication of this study, nor in the supplementary material provided
for participants with unprovoked VTE.We contacted trial authors
to request these data, but they could not provide this information
before completion of this review. Once the data are acquired, we
will add them to future updates of this review.
We planned subgroup analyses by age (≤ 65 years, > 65 years), sex,
renal function, and duration of initial therapy for the acute phase
of VTE. However, we could not perform these subgroup analyses
because participant-level data were insufﬁcient.
Quality of the evidence
See Summary of ﬁndings for the main comparison and Summary
of ﬁndings 2.
For the comparison extended prophylaxis versus placebo and for
the outcomes recurrent VTE and all-cause mortality, we down-
graded the quality of the evidence to moderate owing to concerns
arising from risk of bias in individual studies. One study was at
risk of selection bias (WARFASA), and two studies were at risk
of performance bias (WODIT DVT; WODIT PE). For all other
outcomes in this review (VTE-related mortality, major bleeding,
clinically relevant non-major bleeding, stroke, and serious adverse
events), we downgraded the quality of the evidence to low because
of concerns arising from risks of selection and performance bias
for the studies stated above, combined with concerns over impre-
cision, as reﬂected by small numbers of outcome events and wide
conﬁdence intervals around the estimate of effect for these out-
comes.
For the comparison extended prophylaxis versus extended prophy-
laxis and for the outcomes recurrent VTE, major bleeding, and
clinically relevant non-major bleeding, we downgraded the quality
of the evidence to moderate owing to concerns over imprecision,
as reﬂected by small numbers of outcome events and wide conﬁ-
dence intervals around the estimate of effect for these outcomes.
The single study included under this comparison was at low risk of
bias, so we did not further downgrade the quality of the evidence
(EINSTEIN CHOICE).
Potential biases in the review process
The search was as comprehensive as possible, and we are conﬁdent
that we have included all relevant studies. However, the possibility
remains that we missed some relevant trials, particularly in the
grey literature (e.g. conference proceedings). Two review authors
independently performed study selection and data extraction to
minimise bias in the review process. We performed data collection
according to the process suggested by Cochrane. We also followed
20Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked
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Cochrane processes as described byHiggins 2011 for assessing risk
of bias.
The inclusion criteria for this review stipulate that participants
must have completed at least three months’ anticoagulation treat-
ment before receiving extended prophylaxis. In one of the stud-
ies included in this review, 1% of participants had completed less
than three months’ anticoagulation treatment before randomisa-
tion (ASPIRE TRIAL). We attempted to contact the authors of
this study to obtain outcome data excluding these participants,
but we did not receive a reply. As this number was very small, it is
unlikely to have affected the overall result. Furthermore, the num-
ber excluded from each group was 1% and was equally distributed
between treatments. Therefore, we did not see the need to exclude
this study from the review on this basis.
Similarly, our inclusion criteria required inclusion of participants
aged 18 years and older, and two studies included participants aged
15 to 85 years (WODITDVT;WODITPE).Given that themean
age of participants in the trial was 67 (SD 12.4) years, it is likely
that the trial included only a small number of participants under
18 years of age. Furthermore, as this was a randomised controlled
trial, the number of participants under 18 years of age would be
equally distributed between the two treatment groups, and this is
unlikely to have any effect on the overall result.
Agreements and disagreements with other
studies or reviews
Several researchers have studied DOACs such as dabigatran, ri-
varoxaban, and apixaban for extended treatment of patients with
VTE after the initial anticoagulation period. Four randomised
controlled trials reported that, when compared to placebo or
warfarin, all DOACs demonstrated efﬁcacy in reducing VTE
recurrence, some with lower bleeding rates compared to war-
farin (AMPLIFY EXT; EINSTEIN-Extension; RE-MEDY; RE-
SONATE). One of the studies included in our review compared
rivaroxaban with aspirin and found a reduction in the VTE re-
currence rate among patients treated with rivaroxaban compared
with aspirin (EINSTEINCHOICE).When compared to placebo,
investigators found increased bleeding rates with dabigatran and
rivaroxaban but no increase in the rate of major bleeding with
apixaban (AMPLIFY EXT; EINSTEIN-Extension; RE-MEDY;
RE-SONATE). We excluded these four randomised controlled
trials from the review, as some participants had a previous VTE (
AMPLIFY EXT) or had a provoked VTE (EINSTEIN-Extension;
RE-MEDY; RE-SONATE), and we were unable to obtain data
for participants with unprovoked VTE.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
At present, evidence is insufﬁcient to show whether oral therapeu-
tic options such as aspirin, warfarin, and DOACs provide effec-
tive and safe extended thromboprophylaxis for individuals with a
ﬁrst unprovoked venous thromboembolism (VTE)whohave com-
pleted at least three months of initial oral anticoagulation. As the
question of extended thromboprophylaxis remains unanswered,
physicians must rely on their assessment of risk of recurrence (age,
sex, circumstances of the primary event) and risk of bleeding and
consider the patient’s preference.
Implications for research
The small number of studies included in this systematic review
conﬁrms the need for further methodologically sound and large
randomised controlled trials. Trials should be adequately powered
to show key endpoints. In addition, future studies should identify
groups of patients at highest risk of VTE recurrence and bleeding.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
ASPIRE TRIAL
Methods Study design: double-blind, randomised, placebo-controlled study
Length of follow-up: 4 years
Dates of study: May 2003 to August 2011
Location: 56 sites in 5 countries (Australia, New Zealand, Canada, India, Argentina)
Setting: hospital
Participants Number: 822: aspirin 411, placebo 411
Age, mean (SD) years: aspirin 55 (16.0), placebo 54 (15.8)
Sex: aspirin 226 M/185 F, placebo 221 M/190 F
Ethnic group: not stated
Inclusion criteria: Male and female patients were eligible for inclusion if they were
at least 18 years of age and had a ﬁrst unprovoked episode of objectively diagnosed
symptomatic DVT involving the popliteal vein or more proximal leg veins or an acute
PE. VTE was considered to be unprovoked if it occurred in the absence of the following
transient risk factors during the preceding 2 months: conﬁnement to bed for longer than
1 week, major surgery, trauma requiring a cast, pregnancy or the puerperium, and use of
the oral contraceptive pill or hormone replacement therapy. All patients were required
to have completed initial anticoagulation therapy with heparin followed by warfarin (or
an effective alternative anticoagulant) for between 6 weeks and 24 months
Exclusion criteria: Patients were not eligible for inclusion if the ﬁrst unprovoked episode
of VTE had occurred more than 2 years before enrolment; if they had an indication
or contraindication for the use of aspirin, other antiplatelet therapy, or a non-steroidal
anti-inﬂammatory drug; if they had an indication for continuing oral anticoagulation
therapy; or if they had other medical problems that would interfere with participation
in the trial or would limit life expectancy
Previous DVT or PE: no
Type of VTE at initial diagnosis: apixaban 236 DVT/112 PE/59 DVT + PE, placebo
232 DVT/119 PE/56 DVT+ PE
Creatinine clearance: not stated
Interventions Intervention 1: aspirin 100 mg daily
Intervention 2: placebo 100 mg daily
Duration of treatment: 2 to 4 years
Outcomes Primary: recurrence of VTE (composite of symptomatic, objectively conﬁrmed DVT,
non-fatal PE, or fatal PE) and bleeding (major or clinically relevant non-major bleeding)
. Major bleeding was deﬁned as overt bleeding that was associated with a decrease in
haemoglobin of at least 2 g per decilitre, or that necessitated transfusion of 2 or more
units of blood, involved a critical site (e.g. retroperitoneal or intracranial bleeding), was
disabling, required surgical intervention, or contributed to death. Bleeding episodes that
did not meet the deﬁnition of major bleeding were considered to be clinically relevant
only if they led to discontinuation of the study drug for longer than 14 days
Secondary: major vascular events (a composite of VTE, myocardial infarction, stroke,
or cardiovascular death) and a measure of the net clinical beneﬁt (a reduction in rate of
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ASPIRE TRIAL (Continued)
the composite of VTE myocardial infarction, stroke, major bleeding, or death from any
cause)
Time frame for measuring outcomes: median 37.2 months
Notes 5 (1%) apixaban and 4 (1%) placebo patients had < 3 months’ anticoagulation before
randomisation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomisation was performed
through a central web-based randomisation
system”
Allocation concealment (selection bias) Low risk Quote: “Randomisation was performed
through a central web-based randomisation
system”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind, matching placebo”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “All primary and secondary events
were adjudicated by an independent event
adjudication committee whose members
were unaware of the group assignments”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk Data on all prespeciﬁed primary and sec-
ondary outcomes were reported
Other bias Low risk Study appears to be free from other sources
of bias.
EINSTEIN CHOICE
Methods Study design: multi-centre, randomised, double-blind, active-controlled, event-driven
study
Length of follow-up: 12 months
Dates of study: March 2014 to March 2016
Location: 31 countries
Setting: 230 hospitals
Participants Number: total participants in study 3365: rivaroxaban 2234, aspirin 1131; participants
with unprovoked VTE: rivaroxaban: 921, aspirin: 468
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EINSTEIN CHOICE (Continued)
Age, mean (SD) years: rivaroxaban 58.8 (14.7), aspirin 58.8 (14.7)
Sex: rivaroxaban 1222 M/1012 F, aspirin 643 M/488 F
Ethnic group: not stated
Inclusion criteria: patients with objectively conﬁrmed symptomatic DVT and/or PE
who have completed 6 to 12 months of anticoagulant therapy with warfarin or another
VKA, or with rivaroxaban, apixaban, or dabigatran, who have not interrupted therapy
for more than 7 days before randomisation and who did not experience a symptomatic
recurrence during the anticoagulation period
Exclusion criteria: patients with an indication for therapeutic dose anticoagulants, hy-
persensitivity to investigational or comparator treatment, any other contraindication
listed in the local labelling for investigational or comparator treatment, an indication
for antiplatelet therapy or a conventional non-steroidal anti-inﬂammatory drug, hepatic
disease associated with coagulopathy leading to a clinically relevant bleeding risk, active
bleeding or high risk of bleeding contraindicating anticoagulant therapy, life expectancy
< 6 months, concomitant use of human immunodeﬁciency virus protease inhibitors -
ketoconazole, itraconazole, voriconazole, and posaconazole, childbearing potential with-
out proper contraceptive measures, pregnancy or breast feeding, and participation in a
study with an investigational drug or medical device within 30 days before randomisa-
tion. Additional ineligibility criteria included a calculated creatinine clearance < 30 mL
per minute or hepatic disease associated with a coagulopathy
Creatinine clearance: 30 to < 50 mL/min: 89 rivaroxaban, 63 aspirin; 50 to < 80 mL/
min: 581 rivaroxaban, 277 aspirin; ≥ 80 mL/min: 1561 rivaroxaban, 790 aspirin
Interventions Intervention 1: rivaroxaban 10 mg once daily
Intervention 2: rivaroxaban 20 mg once daily
Intervention 3: aspirin 100 mg once daily
Duration of treatment: 12 months
Outcomes Primary: recurrent symptomatic VTE (including fatal and non-fatal PE and DVT) and
clinically overt major bleeding (associated with a fall in haemoglobin ≥ 2 g/dL, leading
to transfusion of ≥ 2 units of packed red blood cells or whole blood, or occurring in a
critical site (e.g. intracranial, intraocular, pericardial, intra-articular, intramuscular with
compartment syndrome or retroperitoneal, or leading to death)
Secondary: myocardial infarction, ischaemic stroke, non-central nervous system em-
bolism, all-cause mortality, and clinically relevant non-major bleeding (non-major overt
bleeding associated with study drug interruption longer than 14 days)
Time frame for measuring outcomes: 12 months
Notes Please note that for the analysis in this review, we used data for participants with a
diagnosis of an unprovoked index VTE only (number of participants rivaroxaban: 921,
aspirin: 468)
Data on secondary outcomes and VTE mortality for participants with a diagnosis of an
unprovoked index VTE were not available in the main publication of the study, nor in
the supplementary material. We contacted study authors to ask for these data, but they
could not provide this information before completion of this review. Once the data are
acquired, we will add them to future updates of this review
Risk of bias
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EINSTEIN CHOICE (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization with a block size
of six was performed with the use of an
interactive voice-response system”
Allocation concealment (selection bias) Low risk Quote: “Randomization with a block size
of six was performed with the use of an
interactive voice-response system”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Double blind. Rivaroxaban (20
mg and 10mg) andmatching placebo were
provided as identical-appearing, immedi-
ate-release ﬁlm-coated tablets, whereas as-
pirin and matching placebo were provided
as enteric-coated tablets”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “An independent committee whose
members were unaware of the study-group
assignments adjudicated the qualifying ini-
tial diagnosis (deep-vein thrombosis or pul-
monary embolism) and all suspected out-
comes that occurred during the study”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk Data on all prespeciﬁed primary and sec-
ondary outcomes were reported
Other bias Low risk Study appears to be free from other sources
of bias.
PADIS-PE STUDY
Methods Study design: multi-centre, randomised, double-blind, parallel-group trial
Length of follow-up: 42 months
Dates of study: July 2007 to March 2012
Location: France
Setting: 14 hospitals
Participants Number: 371: 184 warfarin, 187 placebo
Age, mean (SD) years: warfarin 58.7 (17.9), placebo 57.3 (17.4)
Sex: warfarin 78 M/106 F, placebo 103 M/84 F
Ethnic group: not stated
Inclusion criteria: patients 18 years of age or older who experienced a ﬁrst episode of
symptomatic unprovoked PE and had been treated initially for 6 uninterrupted months
with a VKA. Unprovoked PE was deﬁned as objectively conﬁrmed symptomatic PE
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PADIS-PE STUDY (Continued)
occurring in the absence of any major reversible risk factor for VTE within 3 months
before diagnosis, including surgery with locoregional or general anaesthesia lasting longer
than 30 minutes, trauma with or without plaster cast of the lower limbs, and bed rest
for longer than 72 hours and in the absence of active cancer or cancer resolved within
the 2 years before diagnosis. Objective tests conﬁrming the index PE were ventilation-
perfusion lung scanning and spiral computerised tomography angiography
Exclusion criteria: Previously conﬁrmed PE or proximal DVT, recurrent VTE, or bleed-
ing during the initial 6-month anticoagulation, known major thrombophilia, indication
for VKA therapy for reasons other than VTE, increased bleeding risk, platelet count
below 100 × 103/µL, major surgery planned within 18 months from randomisation,
and life expectancy less than 18 months
Previous DVT or PE: warfarin 17 DVT, placebo 14 DVT
Type of VTE at initial diagnosis: PE
Creatinine clearance: ≥ 30 to < 50 mL/min warfarin 16, placebo 7; ≥ 50 mL/min
warfarin 164, placebo 173
Interventions Intervention 1: warfarin
Intervention 2: placebo
Duration of treatment: 18 months
Outcomes Primary: symptomatic recurrent VTE (non-fatal PE, fatal PE, and proximal DVT) and
major bleeding at 18 months after randomisation (deﬁned as major if it was clinically
overt and associated with a fall in haemoglobin level ≥ 2.0 g per decilitre, or a need
for transfusion of ≥ 2 units of red cells; if it was retroperitoneal or intracranial; or if it
warranted permanent discontinuation of the study drug)
Secondary: symptomatic recurrent VTE (non-fatal PE, fatal PE, and proximal DVT)
and major bleeding at 42 months after randomisation, and death unrelated to PE or
major bleeding at 18 and 42 months
Time frame for measuring outcomes: 18 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomised using
a central computerised Internet-based sys-
tem. Using a computer algorithm, an inde-
pendent statistician generated the assign-
ment list in randomly permuted blocks. Be-
fore the ﬁrst patient was enrolled, this list
was forwarded to a central anticoagulation
clinic not involved in patient care”
Allocation concealment (selection bias) Low risk Quote: “Patients were randomised using
a central computerised Internet-based sys-
tem”
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PADIS-PE STUDY (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double blind.....identical-looking
placebo....study INRs were determined at
each patient’s usual local laboratory and
sent directly to the anticoagulation clinic.
Patients and investigators remained un-
aware of the local results to maintain dou-
ble-blind conditions. For patients assigned
to receive warfarin, the clinic returned the
true INR results to investigators for dose
adjustments. For those assigned to placebo,
the clinic substituted computer-generated
sham INR results”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “All outcomes were adjudicated
blindly by an independent central critical
events committee. All images for ventila-
tion-perfusion lung scanning, spiral com-
puterised tomographic angiography, and
ultrasonography were reviewed centrally by
independent dedicated panels”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk Data on all prespeciﬁed primary and sec-
ondary outcomes were reported
Other bias Low risk Study appears to be free from other sources
of bias.
WARFASA
Methods Study design: multi-centre, randomised, double-blind, placebo-controlled trial
Length of follow-up: 2 years
Dates of study: May 2004 to August 2010
Location: 25 European Centers in Austria, Denmark, France, Great Britain, Italy, and
the Netherlands
Setting: hospital
Participants Number: 403: 205 aspirin, 198 placebo
Age, mean (SD) years: aspirin 61.9 (15.3), placebo 62.1 (15.1)
Sex: aspirin 135 M/70 F, placebo 122 M/75 F
Ethnic group: aspirin 203 (99%) white, placebo 195 (98.9%) white
Inclusion criteria: patients aged 18 years or older who had been treated for 6 to 18
months with VKAs for a ﬁrst-ever, objectively conﬁrmed, symptomatic, unprovoked
proximal DVT, PE, or both. VTE was considered to be unprovoked when it occurred
in the absence of any known risk factor
Exclusion criteria: known cancer; known major thrombophilia (antiphospholipid anti-
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WARFASA (Continued)
bodies or lupus anticoagulant or homozygous factor V Leiden or prothrombinG21210A
or double heterozygosity for factor V Leiden and prothrombin G21210A or deﬁciency
of antithrombin, protein C or S); an indication for long-term anticoagulant therapy
other than VTE (as atrial ﬁbrillation or prosthetic heart valve); previous symptomatic
complications of atherosclerosis requiring treatment with aspirin or other antiplatelet
agents; active bleeding or high risk for bleeding or a bleeding episode that occurred
during the 6 to 18 months of anticoagulation; known allergy or intolerance to aspirin;
life expectancy shorter than 6 months; anticipated non-adherence to study medications;
pregnancy or breast-feeding; participation in another experimental pharmacotherapeutic
program within 30 days before randomisation. Women with venous thromboembolism
associated with the use of estro-progestin therapy were excluded from the study
Previous DVT or PE: no
Type of VTE at initial diagnosis: aspirin 122 DVT/83 PE, placebo 130 DVT/67 PE
Creatinine clearance: not stated
Interventions Intervention 1: aspirin 100 mg once daily
Intervention 2: placebo
Duration of treatment: 2 years
Outcomes Primary: symptomatic recurrent VTE (DVT, fatal or non-fatal PE) and major bleeding
(deﬁned asmajor if it was clinically overt andwas associatedwith a fall in the haemoglobin
level of ≥ 2.0 g per decilitre or a need for transfusion of ≥ 2 units of red cells; if it was
retroperitoneal or intracranial; or if it warranted permanent discontinuation of the study
drug)
Secondary: arterial events (non-fatal MI, unstable angina, stroke, transient Ischaemic
attack, acute ischaemia of the lower limbs), all-cause mortality, and clinically relevant,
non-major bleeding (any overt bleeding that required a medical intervention and did
not meet any of the criteria for major bleeding)
Time frame for measuring outcomes: 24 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote :“The randomisation sequence will
be computer generated”
Allocation concealment (selection bias) High risk Quote: “Patients will be randomised ac-
cording to the consecutive box number as-
signed to the study centre”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind”
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WARFASA (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “All suspected study outcomeswere
assessed by a central, independent adjudi-
cation committee whosemembers were un-
aware of the group assignments and who
reviewed the imaging results”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk Data on all prespeciﬁed primary and sec-
ondary outcomes were reported
Other bias Low risk Study appears to be free from other sources
of bias.
WODIT DVT
Methods Study design: multi-centre, randomised, open trial
Length of follow-up: 2 years
Dates of study: January 1995 to June 1998
Location: Italy
Setting: hospital
Participants Number: 267: 134 extended anticoagulation, 133 anticoagulation withdrawn
Age, mean (SD) years: 67.0 (12.4)
Sex: 78 M/103 F
Ethnic group: not stated
Inclusion criteria: patients 15 to 85 years of age with a ﬁrst episode of symptomatic,
idiopathic, proximal deep vein thrombosis who had completed 3 uninterrupted months
of oral anticoagulant therapy without having a recurrence of VTE or bleeding. Idio-
pathic DVTwas deﬁned as thrombosis occurring in the absence of cancer, known throm-
bophilia, or any transient risk factor for VTE (recent trauma, recent surgery or child-
birth, prolonged immobilisation > days, oral contraception or pregnancy)
Exclusion criteria: patients who required prolonged anticoagulant therapy for reasons
other than VTE, major psychiatric disorders, and life expectancy less than 2 years
Previous DVT or PE: no
Type of VTE at initial diagnosis: DVT as demonstrated on compression ultrasonog-
raphy or venography
Creatinine clearance: not stated
Interventions Intervention 1: warfarin
Intervention 2: no treatment
Duration of treatment: 9 months
Outcomes Primary: recurrence of symptomatic, objectively conﬁrmed VTE
Secondary: death andmajor bleeding.Deaths were classiﬁed as the result of PE, bleeding,
or another identiﬁable cause, or as unexplained. Bleeding was deﬁned as major if it
was clinically overt and was associated with a decrease in haemoglobin level ≥ 20 g/
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WODIT DVT (Continued)
L or the need to transfuse ≥ 2 units of red blood cells, if it was retroperitoneal or
intracranial, warranted permanent discontinuation of therapy with the study drug, or
required rehospitalisation
Time frame for measuring outcomes: 9 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Low risk Quote: “Randomisation was performed
centrally”.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “open trial”
Comment: Blinding could have been possi-
ble by using identical-looking placebo and
sham INRs
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “independent, blinded assessment
of the outcome events....all suspected out-
come events and all deaths were reviewed
centrally by an independent, external adju-
dication committee whose members were
unaware of the treatment group assign-
ments”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk Data on all prespeciﬁed primary and sec-
ondary outcomes were reported
Other bias Low risk Study appears to be free from other sources
of bias.
WODIT PE
Methods Study design: multi-centre, randomised, open trial
Length of follow-up: 2 years
Dates of study: January 1997 to December 2000
Location: Italy
Setting: hospital
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WODIT PE (Continued)
Participants Number: 181: 90 extended anticoagulation, 91 anticoagulation withdrawn
Age, mean (SD) years: 67.0 (12.4)
Sex: 78 M/103 F
Ethnic group: not stated
Inclusion criteria: patients 15 to 85 years of age with a ﬁrst episode of symptomatic,
idiopathic, objectively conﬁrmed pulmonary embolism who had completed 3 uninter-
ruptedmonths of oral anticoagulant therapywithout having a recurrence or bleeding. Id-
iopathic PE was deﬁned as PE occurring in the absence of cancer, known thrombophilia,
or any transient risk factor for VTE (recent trauma, recent surgery childbirth, prolonged
immobilisation > days, oral contraception or pregnancy)
Exclusion criteria: PE associated with known cancer or thrombophilia, prolonged an-
ticoagulant therapy required for reasons other than VTE, major psychiatric disorders,
and life expectancy less than 2 years
Previous DVT or PE: no
Type of VTE at initial diagnosis: PE
Creatinine clearance: not stated
Interventions Intervention 1: warfarin
Intervention 2: no treatment
Duration of treatment: 9 months
Outcomes Primary: recurrence of symptomatic, objectively conﬁrmed VTE
Secondary: death and major bleeding. Deaths were classiﬁed as resulting from PE,
bleeding, or another identiﬁable cause, or as unexplained. Bleeding was deﬁned as major
if it was clinically overt and was associated with a decrease in haemoglobin level of ≥
20 g/L or the need to transfuse ≥ 2 units of red blood cells, if it was retroperitoneal or
intracranial, warranted permanent discontinuation of therapy with the study drug, or
required rehospitalisation
Time frame for measuring outcomes: 9 months
Notes 11.6% of participants had received thrombolytic treatment.
In total, 326 participants were included in the study, but for the purpose of this review,
we included only the 181 participants with idiopathic PE
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Low risk Quote: “Randomisation was performed
centrally”.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “open trial”
Comment: Blinding could have been possi-
ble by using identical-looking placebo and
sham INRs
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WODIT PE (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “independent, blinded assessment
of the outcome events....all suspected out-
come events and all deaths were reviewed
centrally by an independent, external adju-
dication committee whose members were
unaware of the treatment group assign-
ments”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk Data on all prespeciﬁed primary and sec-
ondary outcomes were reported
Other bias Low risk Study appears to be free from other sources
of bias.
DVT: deep vein thrombosis.
g: grams.
g/dL: grams per decilitre.
g/L: gram per litre.
INR: international normalised ratio.
mg: milligrams.
MI: myocardial infarction.
PE: pulmonary embolism.
SD: standard deviation.
µL: microlitres.
VKA: vitamin K antagonist.
VTE: venous thromboembolism.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
AMPLIFY EXT 13% of apixaban and 12% of placebo participants had a previous VTE. Trial authors were contacted for
data on participants with unprovoked VTE only, but they did not reply
Bleker 2016 Study was on pregnant women with a history of VTE.
EINSTEIN STUDY Study assesses effectiveness of rivaroxaban for initial treatment of PE
EINSTEIN-Extension Over 34% of study participants (412/1196) had an unprovoked VTE. Risk factors for VTE included recent
surgery or trauma, immobilisation, oestrogen therapy, active cancer, or puerperium. Trial authors were
contacted for data on participants with unprovoked VTE only, but they did not reply
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(Continued)
Eischer 2009 Participants had high levels of Factor VIII; therefore the VTE was not unprovoked
Gibson 2017 Study was on acutely ill, hospitalised patients who were at elevated risk of VTE
Kearon 1999 Over a quarter of study participants had a known thrombophilia (26% Factor V Leiden mutation, 5%
G20210A prothrombin gene mutation, and 5% antiphospholipid antibodies). Trial authors were contacted
for data on participants with no known thrombophilia, but they did not reply
Nakamura 2015 Study looked at recurrent VTE rates during initial 24 weeks of treatment
PREVENT Over a quarter of study participants had a known thrombophilia (22% of warfarin-treated and 26.6% of
placebo-treated participants had Factor V Leiden mutation; 4.7% of warfarin and 4.8% of placebo had
G20210A prothrombin mutation). Trial authors were contacted for data on participants with no known
thrombophilia, but they did not reply
RE-COVER Study looked at initial anticoagulant treatment for acute VTE rather than extended prophylaxis
RE-MEDY Over 18% of study participants (525/2856) had a known thrombophilia. Trial authors were contacted for
data on participants with no known thrombophilia, but they did not reply
RE-SONATE Over 10% of study participants (155/1343) had a known thrombophilia. Trial authors were contacted for
data on participants with no known thrombophilia, but they did not reply
SURVET Trial studied the effectiveness of sulodexide, which is a low molecular weight heparin
VAN GOGH Trial studied idraparinux, which is an injectable anticoagulant
Vitovec 2009 The primary outcome of this study was the size of thrombotic masses, which is not relevant to our review
PE: pulmonary embolism.
VTE: venous thromboembolism.
Characteristics of ongoing studies [ordered by study ID]
NCT00740493
Trial name or title Prolonged Anticoagulation After a First Episode of Idiopathic Proximal Deep Vein Thrombosis (PADIS TVP)
Methods Multi-centre, double-blind, randomised, parallel-group trial
Participants Inclusion criteria:
• Patients with a ﬁrst episode of idiopathic proximal DVT who have been treated during 6 months (plus
or minus 15 days) with a VKA with INR between 2 and 3
Exclusion criteria:
• Age > 18 years
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NCT00740493 (Continued)
• Warfarin hypersensibility
• Unwillingness or inability to give written informed consent
• Distal DVT or PE
• Proximal DVT provoked by a reversible major risk factor
• Major thrombophilia (protein C, S or antithrombin deﬁciency, antiphospholipid antibodies,
homozygous Factor V Leiden)
• Previous documented episode of proximal DVT or PE
• Other indication for anticoagulant therapy (e.g. atrial ﬁbrillation, mechanical valve)
• Patient taking antithrombotic agent in whom antithrombotic agent should be started again after
anticoagulation is stopped
• Pregnancy
• Women without contraception
• Planned major surgery in the next 18 months
• Ongoing cancer or cancer cured within 2 years
• Serious bleeding risk (e.g. gastric ulcer)
• Platelet count < 100 × 103/µL
• Life expectancy less than 18 months
Interventions Intervention 1: warfarin
Intervention 2: placebo
Duration: 18 months
Outcomes Primary: symptomatic recurrent venous thromboembolism and serious bleeding
Secondary: mortality due to a cause other than recurrent venous thromboembolism or serious bleeding
Starting date July 2007
Contact information Francis Couturaud, University Hospital, Brest
Notes
DVT: deep vein thrombosis.
INR: international normalised ratio.
PE: pulmonary embolism.
VKA: vitamin K antagonist.
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D A T A A N D A N A L Y S E S
Comparison 1. Extended VTE prophylaxis versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 VTE-related mortality 4 1862 Odds Ratio (M-H, Fixed, 95% CI) 0.98 [0.14, 6.98]
1.1 Warfarin vs placebo 2 638 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Aspirin vs placebo 2 1224 Odds Ratio (M-H, Fixed, 95% CI) 0.98 [0.14, 6.98]
2 Recurrent VTE 5 2043 Odds Ratio (M-H, Random, 95% CI) 0.63 [0.38, 1.03]
2.1 Warfarin vs placebo 3 819 Odds Ratio (M-H, Random, 95% CI) 0.52 [0.15, 1.80]
2.2 Aspirin vs placebo 2 1224 Odds Ratio (M-H, Random, 95% CI) 0.68 [0.50, 0.92]
3 Major bleeding 5 2043 Odds Ratio (M-H, Fixed, 95% CI) 1.84 [0.87, 3.85]
3.1 Warfarin vs placebo 3 819 Odds Ratio (M-H, Fixed, 95% CI) 2.81 [0.89, 8.92]
3.2 Aspirin vs placebo 2 1224 Odds Ratio (M-H, Fixed, 95% CI) 1.28 [0.47, 3.47]
4 All-cause mortality 5 2043 Odds Ratio (M-H, Fixed, 95% CI) 1.00 [0.63, 1.57]
4.1 Warfarin vs placebo 3 819 Odds Ratio (M-H, Fixed, 95% CI) 1.07 [0.53, 2.17]
4.2 Aspirin vs placebo 2 1224 Odds Ratio (M-H, Fixed, 95% CI) 0.95 [0.52, 1.72]
5 Clinically relevant non-major
bleeding
4 1672 Odds Ratio (M-H, Fixed, 95% CI) 1.78 [0.59, 5.33]
5.1 Warfarin vs placebo 2 448 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Aspirin vs placebo 2 1224 Odds Ratio (M-H, Fixed, 95% CI) 1.78 [0.59, 5.33]
6 Stroke 2 1224 Odds Ratio (M-H, Fixed, 95% CI) 1.15 [0.39, 3.46]
6.1 Aspirin vs placebo 2 1224 Odds Ratio (M-H, Fixed, 95% CI) 1.15 [0.39, 3.46]
7 Serious adverse events
(myocardial infarction)
3 1495 Odds Ratio (M-H, Fixed, 95% CI) 1.00 [0.35, 2.87]
7.1 Warfarin vs placebo 1 271 Odds Ratio (M-H, Fixed, 95% CI) 1.02 [0.20, 5.16]
7.2 Aspirin vs placebo 2 1224 Odds Ratio (M-H, Fixed, 95% CI) 0.98 [0.24, 3.94]
Comparison 2. Extended VTE prophylaxis versus another extended VTE prophylaxis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Recurrent VTE 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Major bleeding 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Clinically relevant non-major
bleeding
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
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Analysis 1.1. Comparison 1 Extended VTE prophylaxis versus placebo, Outcome 1 VTE-related mortality.
Review: Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism
Comparison: 1 Extended VTE prophylaxis versus placebo
Outcome: 1 VTE-related mortality
Study or subgroup Prophylaxis Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Warfarin vs placebo
PADIS-PE STUDY 0/184 0/187 Not estimable
WODIT DVT 0/134 0/133 Not estimable
Subtotal (95% CI) 318 320 Not estimable
Total events: 0 (Prophylaxis), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Aspirin vs placebo
ASPIRE TRIAL 1/411 1/411 49.6 % 1.00 [ 0.06, 16.04 ]
WARFASA 1/205 1/197 50.4 % 0.96 [ 0.06, 15.47 ]
Subtotal (95% CI) 616 608 100.0 % 0.98 [ 0.14, 6.98 ]
Total events: 2 (Prophylaxis), 2 (Placebo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
Total (95% CI) 934 928 100.0 % 0.98 [ 0.14, 6.98 ]
Total events: 2 (Prophylaxis), 2 (Placebo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours prophylaxis Favours placebo
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Analysis 1.2. Comparison 1 Extended VTE prophylaxis versus placebo, Outcome 2 Recurrent VTE.
Review: Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism
Comparison: 1 Extended VTE prophylaxis versus placebo
Outcome: 2 Recurrent VTE
Study or subgroup Prophylaxis Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Warfarin vs placebo
PADIS-PE STUDY 3/184 25/187 11.2 % 0.11 [ 0.03, 0.36 ]
WODIT DVT 21/134 21/133 20.9 % 0.99 [ 0.51, 1.92 ]
WODIT PE 11/90 11/91 16.1 % 1.01 [ 0.42, 2.47 ]
Subtotal (95% CI) 408 411 48.1 % 0.52 [ 0.15, 1.80 ]
Total events: 35 (Prophylaxis), 57 (Placebo)
Heterogeneity: Tau2 = 0.98; Chi2 = 11.44, df = 2 (P = 0.003); I2 =83%
Test for overall effect: Z = 1.03 (P = 0.30)
2 Aspirin vs placebo
ASPIRE TRIAL 57/411 73/411 27.7 % 0.75 [ 0.51, 1.09 ]
WARFASA 28/205 43/197 24.2 % 0.57 [ 0.34, 0.96 ]
Subtotal (95% CI) 616 608 51.9 % 0.68 [ 0.50, 0.92 ]
Total events: 85 (Prophylaxis), 116 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.70, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 2.48 (P = 0.013)
Total (95% CI) 1024 1019 100.0 % 0.63 [ 0.38, 1.03 ]
Total events: 120 (Prophylaxis), 173 (Placebo)
Heterogeneity: Tau2 = 0.20; Chi2 = 11.77, df = 4 (P = 0.02); I2 =66%
Test for overall effect: Z = 1.83 (P = 0.067)
Test for subgroup differences: Chi2 = 0.17, df = 1 (P = 0.68), I2 =0.0%
0.01 0.1 1 10 100
Favours prophylaxis Favours placebo
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Analysis 1.3. Comparison 1 Extended VTE prophylaxis versus placebo, Outcome 3 Major bleeding.
Review: Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism
Comparison: 1 Extended VTE prophylaxis versus placebo
Outcome: 3 Major bleeding
Study or subgroup Prophylaxis Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Warfarin vs placebo
PADIS-PE STUDY 4/184 1/187 9.0 % 4.13 [ 0.46, 37.34 ]
WODIT DVT 4/134 2/133 18.1 % 2.02 [ 0.36, 11.19 ]
WODIT PE 3/90 1/91 8.9 % 3.10 [ 0.32, 30.41 ]
Subtotal (95% CI) 408 411 36.0 % 2.81 [ 0.89, 8.92 ]
Total events: 11 (Prophylaxis), 4 (Placebo)
Heterogeneity: Chi2 = 0.27, df = 2 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.76 (P = 0.079)
2 Aspirin vs placebo
ASPIRE TRIAL 8/411 6/411 54.6 % 1.34 [ 0.46, 3.90 ]
WARFASA 1/205 1/197 9.4 % 0.96 [ 0.06, 15.47 ]
Subtotal (95% CI) 616 608 64.0 % 1.28 [ 0.47, 3.47 ]
Total events: 9 (Prophylaxis), 7 (Placebo)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.49 (P = 0.62)
Total (95% CI) 1024 1019 100.0 % 1.84 [ 0.87, 3.85 ]
Total events: 20 (Prophylaxis), 11 (Placebo)
Heterogeneity: Chi2 = 1.28, df = 4 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.61 (P = 0.11)
Test for subgroup differences: Chi2 = 1.02, df = 1 (P = 0.31), I2 =2%
0.001 0.01 0.1 1 10 100 1000
Favours prophylaxis Favours placebo
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Analysis 1.4. Comparison 1 Extended VTE prophylaxis versus placebo, Outcome 4 All-cause mortality.
Review: Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism
Comparison: 1 Extended VTE prophylaxis versus placebo
Outcome: 4 All-cause mortality
Study or subgroup Prophylaxis Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Warfarin vs placebo
PADIS-PE STUDY 2/184 2/187 5.3 % 1.02 [ 0.14, 7.29 ]
WODIT DVT 7/134 7/133 17.9 % 0.99 [ 0.34, 2.91 ]
WODIT PE 8/90 7/91 17.0 % 1.17 [ 0.41, 3.38 ]
Subtotal (95% CI) 408 411 40.2 % 1.07 [ 0.53, 2.17 ]
Total events: 17 (Prophylaxis), 16 (Placebo)
Heterogeneity: Chi2 = 0.05, df = 2 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
2 Aspirin vs placebo
ASPIRE TRIAL 16/411 18/411 46.5 % 0.88 [ 0.44, 1.76 ]
WARFASA 6/205 5/197 13.3 % 1.16 [ 0.35, 3.86 ]
Subtotal (95% CI) 616 608 59.8 % 0.95 [ 0.52, 1.72 ]
Total events: 22 (Prophylaxis), 23 (Placebo)
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
Total (95% CI) 1024 1019 100.0 % 1.00 [ 0.63, 1.57 ]
Total events: 39 (Prophylaxis), 39 (Placebo)
Heterogeneity: Chi2 = 0.26, df = 4 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.99)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.79), I2 =0.0%
0.01 0.1 1 10 100
Favours prophylaxis Favours placebo
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Analysis 1.5. Comparison 1 Extended VTE prophylaxis versus placebo, Outcome 5 Clinically relevant non-
major bleeding.
Review: Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism
Comparison: 1 Extended VTE prophylaxis versus placebo
Outcome: 5 Clinically relevant non-major bleeding
Study or subgroup Prophylaxis Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Warfarin vs placebo
WODIT DVT 0/134 0/133 Not estimable
WODIT PE 0/90 0/91 Not estimable
Subtotal (95% CI) 224 224 Not estimable
Total events: 0 (Prophylaxis), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Aspirin vs placebo
ASPIRE TRIAL 6/411 2/411 39.5 % 3.03 [ 0.61, 15.10 ]
WARFASA 3/205 3/197 60.5 % 0.96 [ 0.19, 4.82 ]
Subtotal (95% CI) 616 608 100.0 % 1.78 [ 0.59, 5.33 ]
Total events: 9 (Prophylaxis), 5 (Placebo)
Heterogeneity: Chi2 = 0.98, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.30)
Total (95% CI) 840 832 100.0 % 1.78 [ 0.59, 5.33 ]
Total events: 9 (Prophylaxis), 5 (Placebo)
Heterogeneity: Chi2 = 0.98, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours prophylaxis Favours placebo
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Analysis 1.6. Comparison 1 Extended VTE prophylaxis versus placebo, Outcome 6 Stroke.
Review: Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism
Comparison: 1 Extended VTE prophylaxis versus placebo
Outcome: 6 Stroke
Study or subgroup Prophylaxis Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Aspirin vs placebo
ASPIRE TRIAL 4/411 5/411 83.1 % 0.80 [ 0.21, 2.99 ]
WARFASA 3/205 1/197 16.9 % 2.91 [ 0.30, 28.22 ]
Total (95% CI) 616 608 100.0 % 1.15 [ 0.39, 3.46 ]
Total events: 7 (Prophylaxis), 6 (Placebo)
Heterogeneity: Chi2 = 0.94, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 0.26 (P = 0.80)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours prophylaxis Favours placebo
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Analysis 1.7. Comparison 1 Extended VTE prophylaxis versus placebo, Outcome 7 Serious adverse events
(myocardial infarction).
Review: Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism
Comparison: 1 Extended VTE prophylaxis versus placebo
Outcome: 7 Serious adverse events (myocardial infarction)
Study or subgroup Prophylaxis Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Warfarin vs placebo
WODIT DVT 3/134 3/137 42.0 % 1.02 [ 0.20, 5.16 ]
Subtotal (95% CI) 134 137 42.0 % 1.02 [ 0.20, 5.16 ]
Total events: 3 (Prophylaxis), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
2 Aspirin vs placebo
ASPIRE TRIAL 2/411 2/411 28.8 % 1.00 [ 0.14, 7.13 ]
WARFASA 2/205 2/197 29.2 % 0.96 [ 0.13, 6.89 ]
Subtotal (95% CI) 616 608 58.0 % 0.98 [ 0.24, 3.94 ]
Total events: 4 (Prophylaxis), 4 (Placebo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.98)
Total (95% CI) 750 745 100.0 % 1.00 [ 0.35, 2.87 ]
Total events: 7 (Prophylaxis), 7 (Placebo)
Heterogeneity: Chi2 = 0.00, df = 2 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.00 (P = 1.0)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.97), I2 =0.0%
0.01 0.1 1 10 100
Favours prophylaxis Favours placebo
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Analysis 2.1. Comparison 2 Extended VTE prophylaxis versus another extended VTE prophylaxis, Outcome
1 Recurrent VTE.
Review: Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism
Comparison: 2 Extended VTE prophylaxis versus another extended VTE prophylaxis
Outcome: 1 Recurrent VTE
Study or subgroup Rivaroxaban Aspirin Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
EINSTEIN CHOICE 15/921 26/468 0.28 [ 0.15, 0.54 ]
0.01 0.1 1 10 100
Favours rivaroxaban Favours aspirin
Analysis 2.2. Comparison 2 Extended VTE prophylaxis versus another extended VTE prophylaxis, Outcome
2 Major bleeding.
Review: Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism
Comparison: 2 Extended VTE prophylaxis versus another extended VTE prophylaxis
Outcome: 2 Major bleeding
Study or subgroup Rivaroxaban Aspirin Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
EINSTEIN CHOICE 6/921 1/468 3.06 [ 0.37, 25.51 ]
0.01 0.1 1 10 100
Favours rivaroxaban Favours aspirin
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Analysis 2.3. Comparison 2 Extended VTE prophylaxis versus another extended VTE prophylaxis, Outcome
3 Clinically relevant non-major bleeding.
Review: Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism
Comparison: 2 Extended VTE prophylaxis versus another extended VTE prophylaxis
Outcome: 3 Clinically relevant non-major bleeding
Study or subgroup Rivaroxaban Aspirin Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
EINSTEIN CHOICE 15/921 9/468 0.84 [ 0.37, 1.94 ]
0.01 0.1 1 10 100
Favours rivaroxaban Favours aspirin
A P P E N D I C E S
Appendix 1. CRS search strategy
Search run on Mon Mar 27 2017
#1 MESH DESCRIPTOR Thrombosis 1267
#2 MESH DESCRIPTOR Thromboembolism 921
#3 MESH DESCRIPTOR Venous Thromboem-
bolism
258
#4 MESH DESCRIPTOR Venous Thrombosis
EXPLODE ALL TREES
2041
#5 (thrombus* or thrombopro* or thrombotic* or
thrombolic* or thromboemboli* or thrombos*
or embol* or microembol*):TI,AB,KY
19072
#6 MESH DESCRIPTOR Pulmonary Embolism
EXPLODE ALL TREES
748
#7 (PE or DVT or VTE):TI,AB,KY 4988
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(Continued)
#8 ((vein* or ven*) near thromb*):TI,AB,KY 6717
#9 (blood near3 clot*):TI,AB,KY 2966
#10 (pulmonary near3 clot*):TI,AB,KY 5
#11 (lung near3 clot*):TI,AB,KY 4
#12 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #
7 OR #8 OR #9 OR #10 OR #11
24711
#13 MESH DESCRIPTOR Anticoagulants 3362
#14 MESH DESCRIPTOR Warfarin EXPLODE
ALL TREES
1168
#15 warfarin*:TI,AB,KY 3007
#16 (vitamin near3 antagonist*):TI,AB,KY 447
#17 VKA:TI,AB,KY 182
#18 *couma*:TI,AB,KY 746
#19 indobufen 82
#20 MESH DESCRIPTOR Platelet Aggregation
Inhibitors EXPLODE ALL TREES
8563
#21 MESH DESCRIPTOR Phosphodiesterase In-
hibitors EXPLODE ALL TREES
5590
#22 MESH DESCRIPTOR Tetrazoles 1857
#23 (antiplatelet* or anti-platelet* or antiaggreg* or
anti-aggreg*):TI,AB,KY
3484
#24 (((platelet or thromboxane or thrombocyte or
cyclooxygenase or cyclo-oxygenase or phospho-
diesterase or ﬁbrinogen or PAR-1) near3 (an-
tagonist or inhibitor))):TI,AB,KY
2436
#25 ((gp* or glycoprotein* or protease or P2Y12 or
TXA2) near3 inhibit*):TI,AB,KY
3327
#26 thienopyridine:TI,AB,KY 284
#27 (ticlopidine or Ticlid):TI,AB,KY 1817
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(Continued)
#28 (clopidogrel or Plavix):TI,AB,KY 3217
#29 (Prasugrel or Efﬁent or Eﬁent or Prasita):TI,
AB,KY
561
#30 (ticagrelor or AZD6140 or Brilinta):TI,AB,KY 521
#31 (elinogrel or PRT060128 or PRT-060128):TI,
AB,KY
8
#32 (cangrelor or AR-C6993* or ARC6993*):TI,
AB,KY
55
#33 (SCH530348 or SCH-530348):TI,AB,KY 21
#34 E5555:TI,AB,KY 6
#35 (terutroban or Triplion):TI,AB,KY 14
#36 (aspirin* or nitroaspirin or ASA):TI,AB,KY 17514
#37 (acetylsalicylic acid):TI,AB,KY 5169
#38 (acetyl salicylic acid*):TI,AB,KY 114
#39 (triﬂusal or disgren):TI,AB,KY 99
#40 (Cilostazol or Pletal or Pletaal):TI,AB,KY 481
#41 (dipyridamol* or Persantine):TI,AB,KY 1136
#42 (OPC-13013 or OPC13013):TI,AB,KY 5
#43 (picotamide or picotinamide):TI,AB,KY 41
#44 satigrel:TI,AB,KY 3
#45 vorapaxar:TI,AB,KY 90
#46 indobufen:TI,AB,KY 82
#47 MESH DESCRIPTOR Antithrombins EX-
PLODE ALL TREES
1290
#48 MESH DESCRIPTOR Hirudin Therapy 75
#49 (thrombin near3 inhib*):TI,AB,KY 528
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(Continued)
#50 hirudin*:TI,AB,KY 369
#51 (BIBR-953* or BIBR953* or BIBR-1048 or
BIBR1048):TI,AB,KY
9
#52 (AZD0837 or AZD-0837):TI,AB,KY 14
#53 MESH DESCRIPTOR Factor Xa Inhibitors 326
#54 (Factor X* near4 (antag* or inhib* or block*)):
TI,AB,KY
634
#55 (FX* near4 (antag* or inhib* or block*)):TI,
AB,KY
50
#56 (10* near4 (antag* or inhib* or block*) ):TI,
AB,KY
1129
#57 *igatran:TI,AB,KY 458
#58 *agatran:TI,AB,KY 157
#59 *ixaban:TI,AB,KY 388
#60 *oxaban:TI,AB,KY 748
#61 *axaban:TI,AB,KY 7
#62 ((DU-176b or DU176b)):TI,AB,KY 11
#63 ((PRT-054021 or PRT054021)):TI,AB,KY 1
#64 ((YM150 or YM-150 or LY517717 or LY-
517717 or DU-176b or DU176*)):TI,AB,KY
41
#65 ((GW813893 or “Tak 442” or TAK442 or
PD0348292 or GSK-813893 or GSK813893)
):TI,AB,KY
3
#66 #13 OR #14 OR #15 OR #16 OR #17 OR #
18 OR #19 OR #20 OR #21 OR #22 OR #
23 OR #24 OR #25 OR #27 OR #28 OR #
29 OR #30 OR #31 OR #32 OR #33 OR #
34 OR #35 OR #36 OR #37 OR #38 OR #
39 OR #40 OR #41 OR #42 OR #43 OR #
44 OR #45 OR #46 OR #47 OR #48 OR #
49 OR #50 OR #51 OR #52 OR #53 OR #
54 OR #55 OR #56 OR #57 OR #58 OR #
42400
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(Continued)
59 OR #60 OR #61 OR #62 OR #63 OR #64
OR #65
#67 MESH DESCRIPTOR Secondary Prevention 2531
#68 MESH DESCRIPTOR Recurrence 10094
#69 secondary:TI,AB,KY 67519
#70 recurr*:TI,AB,KY 38684
#71 reoccur*:TI,AB,KY 129
#72 duration:TI,AB,KY 78656
#73 extended:TI,AB,KY 10203
#74 prolong:TI,AB,KY 2299
#75 (month* or year*):TI,AB,KY 318293
#76 #67 OR #68 OR #69 OR #70 OR #71 OR #
72 OR #73 OR #74 OR #75
400159
#77 #12 AND #66 AND #76 3837
Appendix 2. Trials registry searches
CinicalTrials.gov
196 studies found for
thromboembolism OR embolism OR thrombosis/Condition
AND
recurrence OR reoccurrence OR recurrent/Outcome measures
World Health Organization International Clinical Trials Registry Platform
80 records for 18 trials found for: thromboembolism AND recurrence AND prevent*
72 records for 25 trials found for: thrombosis AND recurrent AND prevent*
82 records for 18 trials found for: embolism AND recurrent AND prevent*
75 records for 16 trials found for: embolism AND recurrence AND prevent*
ISRCTN Register
98 results (recurrence OR reoccurrence OR recurrent) AND (thromboembolism OR embolism OR thrombosis)
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We have incorporated a ’Summary of ﬁndings’ table to adhere to current Cochane standards.
We performed a post hoc sensitivity analysis to investigate effects of the type of baseline VTE when we identiﬁed heterogeneity.
We amended the bleeding outcome ’all bleeding events’ to ’clinically relevant non-major bleeding’ for standardisation of bleeding
reporting purposes.
We presented odds ratios rather than risk ratios for consistency with other reviews on this topic.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Secondary Prevention; Administration, Oral; Anticoagulants [∗administration & dosage; adverse effects]; Aspirin [administration &
dosage; adverse effects]; Hemorrhage [chemically induced]; Myocardial Infarction [epidemiology]; Randomized Controlled Trials as
Topic; Recurrence; Rivaroxaban [administration & dosage; adverse effects]; Stroke [epidemiology]; Venous Thromboembolism [drug
therapy; mortality; ∗prevention & control]; Warfarin [administration & dosage; adverse effects]
MeSH check words
Humans
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